Ranbaxy Gets USFDA Nod for Migraine Drug Medical Video by Pharmacy

Ranbaxy Gets USFDA Nod for Migraine Drug

Rating: 0.0 out of 0 votes

Comments (0)

You need to have the Flash Player installed and a browser with JavaScript support.

Description Ranbaxy has bagged USFDA approval for Imitrex. DRL already sells Imitrex in US markets since November 24, 2008. Analysts expect Ranbaxy to do sales worth $15-20 million in Q4-FY '09. Imitrex has annual sales of $1-1.2 billion globally.
Tags migraine, drug, USFDA, Ranbaxy, NDTV, Profit, India